Catherine Wood's CRSP Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 9.8M shares of CRISPR Therapeutics AG (CRSP) worth $634.29 M, representing 3.78% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in CRSP, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2020, adding 2.2M shares. Largest reduction occurred in Q1 2021, reducing 2.1M shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's CRISPR Therapeutics (CRSP) Holding Value Over Time
Track share changes against reported price movement
Quarterly CRISPR Therapeutics (CRSP) Trades by Catherine Wood
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2017 | +12,888 | New Buy | 12,888 | $15.98 |
| Q4 2017 | +31,389 | Add 0.00% | 31,388 | $23.48 |
| Q1 2018 | +41,146 | Add 131.09% | 72,534 | $45.72 |
| Q2 2018 | +394,606 | Add 544.03% | 467,140 | $58.76 |
| Q3 2018 | +986,450 | Add 211.17% | 1.45 M | $44.35 |
| Q4 2018 | -128,480 | Reduce 8.84% | 1.33 M | $28.57 |
| Q1 2019 | +697,907 | Add 52.67% | 2.02 M | $35.72 |
| Q2 2019 | +701,332 | Add 34.67% | 2.72 M | $47.10 |
| Q3 2019 | +57,791 | Add 2.12% | 2.78 M | $40.99 |
| Q4 2019 | +174,495 | Add 6.27% | 2.96 M | $60.91 |
| Q1 2020 | +1.33 M | Add 44.95% | 4.29 M | $42.41 |
| Q2 2020 | +2.2 M | Add 51.28% | 6.48 M | $73.49 |
| Q3 2020 | +1.97 M | Add 30.45% | 8.46 M | $83.64 |
| Q4 2020 | +1.96 M | Add 23.12% | 10.41 M | $153.11 |
| Q1 2021 | -2.12 M | Reduce 20.38% | 8.29 M | $121.85 |
| Q2 2021 | -514,231 | Reduce 6.20% | 7.78 M | $161.89 |
| Q3 2021 | -190,445 | Reduce 2.45% | 7.59 M | $111.93 |
| Q4 2021 | +1.5 M | Add 19.80% | 9.09 M | $75.78 |
| Q1 2022 | +316,203 | Add 3.48% | 9.4 M | $62.77 |
| Q2 2022 | +323,460 | Add 3.44% | 9.73 M | $58.05 |
| Q3 2022 | -1.49 M | Reduce 15.32% | 8.24 M | $65.35 |
| Q4 2022 | -407,190 | Reduce 4.94% | 7.83 M | $40.65 |
| Q1 2023 | +160,256 | Add 2.05% | 7.99 M | $45.23 |
| Q2 2023 | -651,741 | Reduce 8.16% | 7.34 M | $56.14 |
| Q3 2023 | -175,329 | Reduce 2.39% | 7.16 M | $45.39 |
| Q4 2023 | +1.37 M | Add 19.17% | 8.54 M | $62.60 |
| Q1 2024 | -379,076 | Reduce 4.44% | 8.16 M | $68.16 |
| Q2 2024 | -378,492 | Reduce 4.64% | 7.78 M | $54.01 |
| Q3 2024 | -279,911 | Reduce 3.60% | 7.5 M | $46.98 |
| Q4 2024 | +1.47 M | Add 19.66% | 8.97 M | $39.36 |
| Q1 2025 | +1.19 M | Add 13.29% | 10.17 M | $34.03 |
| Q2 2025 | +17,190 | Add 0.17% | 10.18 M | $48.64 |
| Q3 2025 | -395,617 | Reduce 3.89% | 9.79 M | $64.81 |
Catherine Wood's CRISPR Therapeutics Investment FAQs
Catherine Wood first purchased CRISPR Therapeutics AG (CRSP) in Q2 2017, acquiring 12,888 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held CRISPR Therapeutics AG (CRSP) for 34 quarters since Q2 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood's largest addition to CRISPR Therapeutics AG (CRSP) was in Q2 2020, adding 6,483,251 shares worth $476.45 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 9,786,973 shares of CRISPR Therapeutics AG (CRSP), valued at approximately $634.29 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, CRISPR Therapeutics AG (CRSP) represents approximately 3.78% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood's peak holding in CRISPR Therapeutics AG (CRSP) was 10,412,976 shares, as reported at the end of Q4 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.